Document Detail


Efficacy of long-term lanreotide treatment in patients with acromegaly.
MedLine Citation:
PMID:  19266287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 +/- 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 +/- 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 +/- 26.3 and 579 +/- 177 mug/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 +/- 238 to 276 +/- 147 mug/l (P < 0.001), and mean GH levels, from 5.2 +/- 6.4 to 3.2 +/- 3.0 mug/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (</=2 mug/l) were achieved in 49% of patients. Both IGF-I normalization and safe GH levels were reached in 32% of the cohort. Lanreotide is an effective treatment for active acromegaly. Female sex was associated with higher rates of IGF-I normalization.
Authors:
Yoel Toledano; Liat Rot; Yona Greenman; Sophia Orlovsky; Yulia Pauker; David Olchovsky; Achia Eliash; Orit Bardicef; Ofa Makhoul; Gloria Tsvetov; Michal Gershinsky; Odile Cohen-Ouaqnine; Rosane Ness-Abramof; Zaina Adnan; Jacob Ilany; Hadassah Guttmann; Mazal Sapir; Carlos Benbassat; Ilan Shimon
Related Documents :
18283267 - Consensus statement of the polish society for endocrinology: presurgical somatostatin a...
17415197 - Treatment options for third ventricular colloid cysts: comparison of open microsurgical...
3296637 - Clinical experience with somatonorm.
3923027 - Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor...
3974887 - Long-term study of pergolide in parkinson's disease.
18340987 - Xp bond in self-curing mode used for luting porcelain restorations. part b: placement a...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pituitary     Volume:  12     ISSN:  1573-7403     ISO Abbreviation:  Pituitary     Publication Date:  2009  
Date Detail:
Created Date:  2009-10-20     Completed Date:  2010-02-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9814578     Medline TA:  Pituitary     Country:  United States    
Other Details:
Languages:  eng     Pagination:  285-93     Citation Subset:  IM    
Affiliation:
Unit of Endocrinology & Diabetes, Hillel Yaffe Medical Center, Hadera, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / drug therapy*,  metabolism
Adult
Antineoplastic Agents / therapeutic use*
Female
Human Growth Hormone / metabolism
Humans
Male
Middle Aged
Peptides, Cyclic / therapeutic use*
Retrospective Studies
Somatomedins / metabolism
Somatostatin / analogs & derivatives*,  therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Peptides, Cyclic; 0/Somatomedins; 118992-92-0/lanreotide; 12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Self-limited acute hepatotoxicity caused by pegvisomant.
Next Document:  Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced set...